{
  "source": "PA-Med-Nec-Winlevi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2241-4\nProgram Prior Authorization/Medical Necessity\nMedications Winlevi® (clascoterone)\nP&T Approval Date 6/2021, 6/2022, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nWinlevi (clascoterone) is an androgen receptor inhibitor indicated for the topical treatment\nof acne vulgaris in patients 12 years of age and older. Guidelines from the American\nAcademy of Dermatology recommend topical therapies for mild acne including retinoids,\nbenzoyl peroxide, topical antibiotics in combination with benzoyl peroxide or topical\nretinoid with a strong recommendation. Clascoterone, salicylic acid and azelaic acid have\nconditional recommendations.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Winlevi* will be approved based on all of the following criteria:\na. Diagnosis of acne vulgaris\n-AND-\nb. Patient is 12 years of age or older\n-AND-\nc. History of failure, contraindication, or intolerance to an adequate trial of a topical\nretinoid [(e.g. tretinoin (generic Retin-A)]\n-AND-\nd. History of failure, contraindication, or intolerance to an adequate trial of a topical\nantibiotic in combination with benzoyl peroxide [e.g., benzoyl\nperoxide/clindamycin (generic Duac), benzoyl peroxide/erythromycin (generic\nBenzamycin)]\n-AND-\ne. History of failure, contraindication, or intolerance to an adequate trial of a topical\ndapsone (e.g. generic Aczone).\nAuthorization will be issued for 6 months.\n© 2024 UnitedHealthcare Services, Inc.\n1\nB. Reauthorization\n1. Winlevi* will be approved based on the following criteria:\na. Documentation of positive clinical response to therapy\n-AND-\nb. Patient has been assessed for signs of hypothalamus-pituitary-adrenal (HPA) axis\nsuppression (e.g. fatigue, weight loss, abdominal pain, depression, muscle\nweakness)\nReauthorization will be issued for 6 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact c",
    "epression, muscle\nweakness)\nReauthorization will be issued for 6 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class\n• Supply limits may be in place.\n*Typically excluded from coverage.\n4. References:\n1. Winlevi [package insert]. Cranbury NJ: Sun Pharmaceuticals Industries, Inc; July 2022.\n2. Reynolds, Rachel V. et al. Guidelines of care for the management of acne vulgaris. J\nAm Acad Dermatol 2024;90:1006.e1-30\nProgram Prior Authorization/Medical Necessity - Winlevi\nChange Control\nDate Change\n6/2021 New program\n6/2022 Annual review. Updated references.\n7/2023 Annual review. Updated example to generic. Updated references.\n7/2024 Annual review. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}